A genetic phenomenon called chromothripsis, or "chromosome shattering," may have spontaneously cured the first person to be documented with WHIM syndrome, according to researchers at the National Institutes of Health (NIH). The patient was the subject of a 1964 study that first described the disorder, a syndrome of recurrent infections, warts and cancer caused by the inability of immune cells, particularly infection-fighting neutrophils, to leave the bone marrow and enter the bloodstream. In 2003, researchers identified the genetic mutations responsible for the disease, which occur in the CXCR4 gene.
As an adult, the patient contacted NIH's National Institute of Allergy and Infectious Diseases (NIAID) to evaluate herself and two of her children, who eventually were diagnosed with WHIM syndrome. The patient reported that her symptoms resolved in her 30s, indicating that she had maintained disease remission for nearly 20 years.
In their study, NIAID researchers identify chromothripsis, the abrupt fragmentation of a chromosome, as the reason for the cure. Such severe changes often cause cells to die, unless they confer a survival advantage, which occurs during the development of some cancers. The researchers show that chromothripsis caused a random and fortuitous deletion of the mutant CXCR4 gene in the patient. Presumably, a stem cell lacking mutant CXCR4 survived and eventually repopulated all of the patient's neutrophils, which now appear to function normally. The study is the first to link chromothripsis to a positive outcome.
There currently are no approved treatments for WHIM syndrome, but NIAID scientists are evaluating the drug plerixafor in clinical trials with promising results. Researchers also are exploring how to apply the study findings to improve bone marrow transplantation, which relies on the ability of donor stem cells to repopulate in a recipient.
McDermott DH et al. Chromothriptic cure of WHIM syndrome. Cell DOI:10.1016/j.cell.2015.01.014 (2015).
Philip Murphy, M.D., Section Chief, David McDermott, M.D., Staff Clinician and Ji-Liang Gao, Ph.D., Staff Scientist in the Molecular Signaling Section of NIAID's Laboratory of Molecular Immunology are available to discuss the findings.
To schedule interviews, please contact Linda Huynh, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®